Trial Profile
An Open-Label, First-In-Human Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Pancreatic beta cell replacement therapy-ViaCyte (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors ViaCyte Inc
- 14 Nov 2023 Status changed from active, no longer recruiting to completed.
- 06 Sep 2023 Results published in the Journal of Clinical Endocrinology and Metabolism
- 24 May 2023 Planned End Date changed from 1 Feb 2024 to 1 Sep 2024.